Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis.

Szczegóły
Abstrakt

Tytuł:: Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis.
Autorzy:: Srivastava R; Department of Pharmacology and Clinical Research, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India.
Kumar A; Department of Pharmacology and Clinical Research, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India.; Department of Pharmacology, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences & Research University (DPSRU), New Delhi, India.
Źródło:: International journal of clinical practice [Int J Clin Pract] 2021 Nov; Vol. 75 (11), pp. e14515. Date of Electronic Publication: 2021 Jun 28.
Typ publikacji:: Meta-Analysis
Język:: English
Imprint Name(s):: Publication: 2022- : Mumbai : Hindawi
Original Publication: Esher [England] ; Bronxville, N.Y. : Medicom International, c1997-
MeSH Terms:: COVID-19*
Respiratory Distress Syndrome*
Aspirin/therapeutic use ; Humans ; SARS-CoV-2
References:: Am J Cardiol. 2021 Mar 1;142:158-159. (PMID: 33417877)
Tohoku J Exp Med. 2020;251(4):327-336. (PMID: 32788506)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
J Cell Mol Med. 2021 Jan;25(2):1263-1273. (PMID: 33336936)
Pharmacotherapy. 2020 Nov;40(11):1130-1151. (PMID: 33006163)
Surgery. 2020 Dec;168(6):987-992. (PMID: 33039110)
Mayo Clin Proc. 2020 Nov;95(11):2467-2486. (PMID: 33153635)
FEBS J. 2021 Sep;288(17):5179-5189. (PMID: 33621437)
Anesth Analg. 2021 Apr 1;132(4):930-941. (PMID: 33093359)
PLoS One. 2021 Feb 11;16(2):e0246825. (PMID: 33571280)
Medicine (Baltimore). 2021 Feb 12;100(6):e24544. (PMID: 33578548)
Shock. 2018 Jun;49(6):616-624. (PMID: 29176404)
J Thromb Haemost. 2020 May;18(5):1094-1099. (PMID: 32220112)
Semin Thromb Hemost. 2020 Oct;46(7):763-771. (PMID: 32882719)
JAMA. 2020 Apr 7;323(13):1239-1242. (PMID: 32091533)
J Thromb Haemost. 2020 Jun;18(6):1516-1517. (PMID: 32294289)
Int J Clin Pract. 2021 Nov;75(11):e14515. (PMID: 34118111)
Pharmacol Res. 2020 Aug;158:104950. (PMID: 32450344)
J Infect. 2021 Jun;82(6):276-316. (PMID: 33577902)
Tohoku J Exp Med. 2020;252(1):73-84. (PMID: 32908083)
Am J Hematol. 2020 Jul;95(7):834-847. (PMID: 32282949)
Cardiorenal Med. 2020;10(6):462-469. (PMID: 33091905)
Thromb Res. 2020 Jul;191:9-14. (PMID: 32353746)
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120. (PMID: 32172226)
PLoS One. 2016 May 16;11(5):e0154754. (PMID: 27182704)
Substance Nomenclature:: R16CO5Y76E (Aspirin)
Entry Date(s):: Date Created: 20210612 Date Completed: 20211022 Latest Revision: 20221005
Update Code:: 20240104
PubMed Central ID:: PMC8420464
DOI:: 10.1111/ijcp.14515
PMID:: 34118111
: Raport

Full Text Finder

COVID-19 infection, affecting every one of us from the last year. Emerging reports have indicated thromboembolism in serious cases of COVID-19. The aspirin is useful to reduce mortality of serious patients with acute respiratory distress syndrome without COVID-19. Thus, we have conducted a metanalysis to find out the role of aspirin in the mortality of COVID-19 patients using RevMan 5. A total of 10 studies containing 56 696 COVID-19 patients were found appropriate for quantitative analysis. The quality of articles was assessed using Newcastle-Ottawa scale. The fixed-effect model was used to calculate the odds ratio with 95% confidence interval (CI). The odd ratio was found to be 0.70 [0.63, 0.77] which indicates a lesser likelihood of having death in COVID-19 patients in aspirin group as compared with non-aspirin group. However, no effect 0.00 [-0.04, 0.04] was observed after the exclusion of outliers. Thus, further clinical evidence is required to make valid conclusion.
(© 2021 John Wiley & Sons Ltd.)

Informacja